Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.46 |
| ▸ | PLK1 | P53350 | 3/20 | 0.44 |
| ▸ | INSR | P06213 | 3/20 | 0.41 |
| ▸ | IGF1R | P08069 | 3/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26401974 | 0.91 | EGFR (0.56) | EGFRLRRK2 | |
| SCHEMBL26402194 | 0.83 | EGFR (0.55) | EGFRLRRK2 | |
| SCHEMBL26398751 | 0.80 | EGFR (0.58) | EGFRPLK1INSRIGF1RALK | |
| SCHEMBL26389545 | 0.79 | EGFR (0.51) | EGFRPLK1INSRIGF1RALK | |
| SCHEMBL26379973 | 0.78 | EGFR (0.55) | EGFRINSRIGF1RALKLRRK2 | |
| SCHEMBL26389509 | 0.78 | EGFR (0.54) | EGFRPLK1INSRIGF1RALK | |
| SCHEMBL26398800 | 0.78 | EGFR (0.56) | EGFRPLK1INSRIGF1RALK | |
| SCHEMBL26398596 | 0.77 | ALK (0.47) | EGFRPLK1INSRIGF1RALK | |
| SCHEMBL26383829 | 0.77 | LRRK2 (0.59) | EGFRLRRK2 | |
| SCHEMBL25144683 | 0.77 | EGFR (0.67) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20170182042-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | SIGNAL PHARM LLC (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182042-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | CYP11B2, CYP27A1, CYP11B1 | EGFR 4290/4885PLK1 2080/4885INSR 668/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885PLK1 267/4885INSR 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.